Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Revenue (2022 - 2025)

Historic Revenue for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $49.5 million.

  • Phathom Pharmaceuticals' Revenue rose 20273.97% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year increase of 46029.69%. This contributed to the annual value of $55.3 million for FY2024, which is 800146.63% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Revenue of $49.5 million as of Q3 2025, which was up 20273.97% from $39.5 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Revenue ranged from a high of $49.5 million in Q3 2025 and a low of -$9.6 million during Q4 2022
  • For the 4-year period, Phathom Pharmaceuticals' Revenue averaged around $12.2 million, with its median value being $4.6 million (2024).
  • Its Revenue has fluctuated over the past 5 years, first surged by 10710.27% in 2023, then soared by 424956.01% in 2024.
  • Phathom Pharmaceuticals' Revenue (Quarter) stood at -$9.6 million in 2022, then skyrocketed by 107.1% to $682000.0 in 2023, then soared by 4249.56% to $29.7 million in 2024, then surged by 66.88% to $49.5 million in 2025.
  • Its Revenue stands at $49.5 million for Q3 2025, versus $39.5 million for Q2 2025 and $28.5 million for Q1 2025.